Newcotiana · Project

Turning Tobacco Plants into Living Factories for Biopharmaceuticals and Health Products

healthTestedTRL 5

Imagine tobacco plants, but instead of making cigarettes, they grow medicine. Researchers used precision gene-editing tools like CRISPR to redesign tobacco and its Australian cousin into miniature pharmaceutical factories that churn out valuable proteins and health compounds. Think of it like reprogramming a car assembly line — same factory floor, completely different product. The goal is to give declining tobacco-farming regions a new cash crop while giving pharma companies a cheaper, greener way to produce biologics.

By the numbers

EUR 7,199,560

EU funding invested in developing the plant biofactory platform

consortium partners across research and industry

countries represented in the development consortium

SMEs involved in the project

project deliverables produced

industry partners validating commercial potential

The business problem

What needed solving

Producing biopharmaceuticals and health compounds through traditional methods (mammalian cell cultures, chemical synthesis) is expensive, slow, and hard to scale. Meanwhile, tobacco farming across the EU is in serious decline, leaving rural communities without economic alternatives. There is a gap between the potential of plants as low-cost biological factories and the availability of crop varieties actually engineered and validated for molecular farming at pre-industrial scale.

The solution

What was built

The project built an advanced CRISPR/Cas9 genome-editing toolbox for Nicotiana species and created elite plant varieties optimized for producing valuable proteins and health-related metabolites. A confirmed deliverable is a stable N. benthamiana line expressing intronized Cas9, and the varieties were tested in pre-industrial production environments across 18 total deliverables.

Audience

Who needs this

Biopharmaceutical CDMOs looking for cheaper protein production platformsNutraceutical companies sourcing rare plant-derived bioactive compoundsAgricultural biotech firms seeking licensable CRISPR crop-editing toolsTobacco-growing regions seeking economic diversification strategiesCosmetics ingredient suppliers wanting plant-based active compounds

Business applications

Who can put this to work

Biopharmaceutical manufacturing

enterprise

Target: Contract development and manufacturing organizations (CDMOs) producing recombinant proteins or biosimilars

If you are a CDMO struggling with the high cost and slow timescale of mammalian cell-based protein production — this project developed CRISPR-optimized Nicotiana plant lines tested in pre-industrial settings that can produce therapeutic proteins and metabolites at high yield. With 21 consortium partners including 7 industry players validating the approach, this offers a plant-based production alternative that could cut your biologics manufacturing costs.

Nutraceuticals and functional ingredients

mid-size

Target: Companies sourcing plant-derived bioactive compounds for supplements, cosmetics, or functional foods

If you are a nutraceutical company paying premium prices for rare plant metabolites — this project bred elite Nicotiana varieties with enhanced secondary metabolism specifically optimized for producing health-related chemicals. The varieties were tested in relevant pre-industrial environments across 8 countries, meaning the supply chain feasibility has been explored beyond the lab.

Agricultural biotech and seed companies

any

Target: Plant breeding companies looking to license advanced gene-editing toolboxes for crop improvement

If you are a plant breeding company looking to adopt CRISPR-based crop improvement — this project built what they describe as the most advanced tobacco breeding toolbox, designed to be easily transferable to other plant species. With 5 SMEs in the consortium and 18 deliverables produced over 5 years of development, this is a mature toolkit covering genome editing, cisgenesis, and grafting techniques.

Frequently asked

Quick answers

What would it cost to access this plant-based production platform?

The project received EUR 7,199,560 in EU funding across 21 partners over 5 years, indicating substantial R&D investment. Licensing costs for the breeding toolbox or elite plant lines would need to be negotiated directly with the consortium coordinator (CSIC, Spain). Based on available project data, no commercial pricing has been published.

Can this scale to industrial production volumes?

The project explicitly tested elite Nicotiana varieties in 'relevant pre-industrial environments' for producing end-value chemicals, proteins, and metabolites. This suggests the technology has moved beyond lab scale but has not yet reached full commercial manufacturing. The 33% industry ratio in the consortium (7 out of 21 partners) indicates real industrial interest in scaling.

What is the IP situation — can I license these plant lines or tools?

With 18 deliverables and a consortium of 21 partners across 8 countries, IP is likely shared among multiple institutions. The coordinator is CSIC (Spanish National Research Council). Any licensing arrangement would need to account for the contributions of 5 SMEs and 7 industry partners already in the consortium.

Is CRISPR-edited tobacco legally allowed in the EU market?

The project specifically monitored ethical, social, and legal aspects of New Plant Breeding Techniques. EU regulation of gene-edited crops remains a live issue — the legal classification of CRISPR-edited plants (as GMO or conventional breeding) directly affects market access. The project used techniques designed to avoid introducing foreign DNA, which may affect regulatory classification.

How long before these plant varieties are commercially available?

The project ran from 2018 to 2022 and is now closed. Pre-industrial testing was completed, but commercial deployment would require additional regulatory approvals and scale-up investment. Based on available project data, no commercial launch timeline has been announced.

Could this technology work for crops other than tobacco?

Yes — the project explicitly states the breeding toolbox was designed to be 'easily transferable to other plants.' The CRISPR/Cas9 platform and associated techniques (cisgenesis, grafting) are not tobacco-specific, making this relevant for any company working on plant-based production systems.

What specific products were these plants engineered to produce?

The project targeted two categories: proteins (including biopharmaceuticals) and metabolites (for health and nutraceutical use). The stable N. benthamiana line expressing intronized Cas9 is one confirmed deliverable. Specific end-product identities would need to be confirmed with the consortium.

Consortium

Who built it

The Newcotiana consortium is unusually large at 21 partners across 8 countries (AT, AU, BE, CH, DE, ES, IT, UK), giving it broad geographic reach and credibility. With 7 industry partners and 5 SMEs making up 33% of the consortium, there is meaningful private-sector involvement — not just an academic exercise. The mix of 6 universities and 8 research institutes provides deep scientific backing, while the industry partners signal that commercial viability was actively explored. The coordinator, CSIC (Spain's national research council), is one of Europe's largest public research bodies, which adds institutional weight. The inclusion of Australian partners reflects the importance of N. benthamiana, which originates from Australia. For a business considering this technology, the consortium size means broad expertise but also potentially complex IP arrangements across multiple jurisdictions.

AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICASCoordinator · ES
IDOASIS 2002 SLparticipant · ES
QUEENSLAND UNIVERSITY OF TECHNOLOGY - QLD QUTparticipant · AU
BIOFACTION KGparticipant · AT
ASOCIACION EMPRESARIAL DE INVESTIGACION CENTRO TECNOLOGICO NACIONAL AGROALIMENTARIO EXTREMADURAparticipant · ES
NATAC BIOTECH SLthirdparty · ES
AGENZIA NAZIONALE PER LE NUOVE TECNOLOGIE, L'ENERGIA E LO SVILUPPO ECONOMICO SOSTENIBILEparticipant · IT
JOHN INNES CENTREparticipant · UK
KARLSRUHER INSTITUT FUER TECHNOLOGIEparticipant · DE
VIB VZWparticipant · BE
UNIVERSITAET FUER BODENKULTUR WIENparticipant · AT
ST GEORGE'S HOSPITAL MEDICAL SCHOOLparticipant · UK
LEIBNIZ-INSTITUT FUR PFLANZENBIOCHEMIEparticipant · DE
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORDparticipant · UK
MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EVparticipant · DE
ROYAL HOLLOWAY AND BEDFORD NEW COLLEGEparticipant · UK

How to reach the team

CSIC (Agencia Estatal Consejo Superior de Investigaciones Cientificas), Spain — reach out via their technology transfer office

Order a report on this consortium See AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS profile →

Next steps

Talk to the team behind this work.

Want an introduction to the Newcotiana team? SciTransfer can connect you with the right consortium partner for your specific production needs — whether that is licensing the CRISPR toolbox, sourcing elite plant lines, or exploring contract biomanufacturing.

Order a report on this topic More in Health & Biomedical